News | Clinical Decision Support | August 13, 2018

ACR LI-RADS Steering Committee Releases New Version of CT/MRI LI-RADS

Update guideline integrates with American Association for the Study of Liver Disease guidance to unify hepatocellular carcinoma diagnostic imaging criteria

ACR LI-RADS Steering Committee Releases New Version of CT/MRI LI-RADS

August 13, 2018 — The American College of Radiology Liver Imaging Reporting and Data System (LI-RADS) steering committee developed and approved a new version of CT/MRI LI-RADS (v2018). The approval reaches a critical milestone of integration into the American Association for the Study of Liver Diseases (AASLD) 2018 hepatocellular carcinoma (HCC) clinical practice guidance.

“By implementing two minor changes to CT/MRI LI-RADS, we were able to unify LI-RADS with AASLD,” said Claude B. Sirlin, M.D., chair, LI-RADS Steering Committee. “Harmonizing these two guidance systems for liver imaging will further reduce imaging interpretation variability and errors, enhance communication with referring clinicians, enable the collection of standardized data and ultimately yield better patient outcomes.”

LI-RADS v2018 revises the definition of the LI-RADS major feature threshold growth and revises one LI-RADS category 5 criterion (10-19 mm + arterial phase hyperenhancement + “washout” = LR-5). The ACR intends to return to a three- to four-year update cycle, with the next major comprehensive update to LI-RADS CT (computed tomography)/MRI (magnetic resonance imaging) anticipated in 2021.

View the update LI-RADS CT/MRI v2018 Core here.

For more information: www.acr.org

Related Content

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017.

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017, and who had health records for at least one year prior to the mammogram. The algorithm was trained on 9,611 mammograms. Image courtesy of Radiology.

Feature | Artificial Intelligence | July 19, 2019 | Michal Chorev
Breast cancer is the global leading cause of cancer-related deaths in women, and the most commonly diagnosed cancer...
Videos | Computed Tomography (CT) | July 19, 2019
Quynh Truong, M.D., MPH, associate professor of radio
Low Doses of Radiation Promote Cancer-capable Cells
News | Radiation Dose Management | July 18, 2019
Low doses of radiation equivalent to three computed tomography (CT) scans, which are considered safe, give cancer-...
Paragon Biosciences Launches Qlarity Imaging to Advance FDA-cleared AI Breast Cancer Diagnosis System

Qlarity Imaging’s software is used to assist radiologists in the assessment and characterization of breast lesions. Imaging features are synthesized by an artificial intelligence algorithm into a single value, the QI score, which is analyzed relative to a database of reference abnormalities with known ground truth. Image courtesy of Business Wire.

Technology | Artificial Intelligence | July 18, 2019
Paragon Biosciences LLC announced the launch of its seventh portfolio company, Qlarity Imaging LLC, which was founded...
Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Feature | Contrast Media | July 18, 2019 | By Greg Freiherr
Macrocyclic contrast agents have the best safety profile of all the magnetic resonance (MR) contrast media that are n
Johns Hopkins Named Qualified Provider-led Entity to Develop Criteria for Diagnostic Imaging
News | Clinical Decision Support | July 18, 2019
On June 30, 2019, the Centers for Medicare & Medicaid Services (CMS) announced the Johns Hopkins University School...
New Lung Ambition Alliance Aims to Double Five-year Lung Cancer Survival by 2025
News | Lung Cancer | July 17, 2019
The International Association for the Study of Lung Cancer (IASLC), Guardant Health, the Global Lung Cancer Coalition (...
AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...